{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T18:16:16Z","timestamp":1766600176925,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-023-05376-5","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T02:02:00Z","timestamp":1688522520000},"page":"1871-1883","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study"],"prefix":"10.1007","volume":"43","author":[{"given":"Panagiotis","family":"Athanassiou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Psaltis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Georgiadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gkikas","family":"Katsifis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athina","family":"Theodoridou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souzana","family":"Gazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prodromos","family":"Sidiropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria G.","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Bounas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kandyli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Periklis","family":"Vounotrypidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grigorios T.","family":"Sakellariou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Vassilopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2657-8567","authenticated-orcid":false,"given":"Evangelia","family":"Petrikkou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"5376_CR1","doi-asserted-by":"publisher","unstructured":"Kr\u00fcger K, Burmester GR, Wassenberg S, Bohl-B\u00fchler M, Thomas MH (2018) Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. BMJ Open 8(6):e021082. https:\/\/doi.org\/10.1136\/bmjopen-2017-021082","DOI":"10.1136\/bmjopen-2017-021082"},{"issue":"10055","key":"5376_CR2","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023\u20132038. https:\/\/doi.org\/10.1016\/S0140-6736(16)30173-8","journal-title":"Lancet"},{"issue":"10136","key":"5376_CR3","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U (2018) The pathogenesis of psoriatic arthritis. Lancet 391(10136):2273\u20132284. https:\/\/doi.org\/10.1016\/S0140-6736(18)30830-4","journal-title":"Lancet"},{"issue":"10089","key":"5376_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390(10089):73\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(16)31591-4","journal-title":"Lancet"},{"key":"5376_CR5","doi-asserted-by":"publisher","unstructured":"Michelsen B, Fiane R, Diamantopoulos AP et al (2015) A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS One 10(4): e0123582. https:\/\/doi.org\/10.1371\/journal.pone.0123582","DOI":"10.1371\/journal.pone.0123582"},{"issue":"6","key":"5376_CR6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5376_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700\u2013712. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5376_CR8","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978\u2013991. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770","journal-title":"Ann Rheum Dis"},{"key":"5376_CR9","doi-asserted-by":"publisher","unstructured":"Rubbert-Roth A, Szab\u00f3 MZ, Kedves M, Nagy G, Atzeni F, Sarzi-Puttini P (2019) Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. Autoimmun Rev 18(12):102398. https:\/\/doi.org\/10.1016\/j.autrev.2019.102398","DOI":"10.1016\/j.autrev.2019.102398"},{"issue":"6","key":"5376_CR10","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s10067-019-04446-z","volume":"38","author":"R Alten","year":"2019","unstructured":"Alten R, Conaghan PG, Strand V et al (2019) Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study. Clin Rheumatol 38(6):1615\u20131626. https:\/\/doi.org\/10.1007\/s10067-019-04446-z","journal-title":"Clin Rheumatol"},{"issue":"4","key":"5376_CR11","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s12325-022-02064-x","volume":"39","author":"X Juanola","year":"2022","unstructured":"Juanola X, Ramos MJM, Belzunegui JM, Fern\u00e1ndez-Carballido C, Gratac\u00f3s J (2022) Treatment failure in axial spondyloarthritis: insights for a standardized definition. Adv Ther 39(4):1490\u20131501. https:\/\/doi.org\/10.1007\/s12325-022-02064-x","journal-title":"Adv Ther"},{"issue":"2","key":"5376_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40744-017-0078-y","volume":"4","author":"V Strand","year":"2017","unstructured":"Strand V, Miller P, Williams SA, Saunders K, Grant S, Kremer J (2017) Discontinuation of biologic therapy in rheumatoid arthritis: analysis from the corrona RA registry. Rheumatol Ther 4(2):489\u2013502. https:\/\/doi.org\/10.1007\/s40744-017-0078-y","journal-title":"Rheumatol Ther"},{"issue":"1","key":"5376_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","volume":"57","author":"C Stober","year":"2018","unstructured":"Stober C, Ye W, Guruparan T, Htut E, Clunie G, Jadon D (2018) Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis. Rheumatology (Oxford) 57(1):158\u2013163. https:\/\/doi.org\/10.1093\/rheumatology\/kex387","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5376_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13075-020-02288-8","volume":"22","author":"SR Manica","year":"2020","unstructured":"Manica SR, Sepriano A, Pimentel-Santos F et al (2020) Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant? Arthritis Res Ther 22(1):195. https:\/\/doi.org\/10.1186\/s13075-020-02288-8","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"5376_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13075-019-1917-8","volume":"21","author":"D Choquette","year":"2019","unstructured":"Choquette D, Bessette L, Alemao E et al (2019) Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata\u00ae clinical database and registry. Arthritis Res Ther 21(1):138. https:\/\/doi.org\/10.1186\/s13075-019-1917-8","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"5376_CR16","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/annrheumdis-2021-221640","volume":"81","author":"L Gossec","year":"2021","unstructured":"Gossec L, Siebert S, Bergmans P et al (2021) Persistence and effectiveness of the IL-12\/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Ann Rheum Dis 81(6):823\u2013830. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221640","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"5376_CR17","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00296-021-05024-w","volume":"42","author":"DI Bekele","year":"2022","unstructured":"Bekele DI, Cheng E, Reimold A et al (2022) Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis. Rheumatol Int 42(11):1925\u20131937. https:\/\/doi.org\/10.1007\/s00296-021-05024-w","journal-title":"Rheumatol Int"},{"key":"5376_CR18","unstructured":"European Medicines Agency. Simponi Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/simponi-epar-product-information_en.pdf. Accessed 06 June 2023"},{"issue":"3","key":"5376_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.55563\/clinexprheumatol\/zizo0l","volume":"39","author":"RM Flipo","year":"2021","unstructured":"Flipo RM, Tubach F, Goupille P et al (2021) Real-life persistence of golimumab in patients with chronic inflammatory rheumatic diseases: results of the 2-year observational GO-PRACTICE study. Clin Exp Rheumatol 39(3):537\u2013545. https:\/\/doi.org\/10.55563\/clinexprheumatol\/zizo0l","journal-title":"Clin Exp Rheumatol"},{"key":"5376_CR20","doi-asserted-by":"publisher","unstructured":"Alegre-Sancho JJ, Juanola X, Rodr\u00edguez-Heredia JM et al (2021) Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis: a retrospective study. Medicine (Baltimore) 100(13):e25223. https:\/\/doi.org\/10.1097\/MD.0000000000025223","DOI":"10.1097\/MD.0000000000025223"},{"key":"5376_CR21","doi-asserted-by":"publisher","unstructured":"Iannone F, Favalli EG, Caporali R et al (2021) Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. Joint Bone Spine 88(1):105062. https:\/\/doi.org\/10.1016\/j.jbspin.2020.07.011","DOI":"10.1016\/j.jbspin.2020.07.011"},{"issue":"10","key":"5376_CR22","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2217\/imt-2020-0296","volume":"13","author":"S Akar","year":"2021","unstructured":"Akar S, Kalyoncu U, Dalkilic E et al (2021) GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey. Immunotherapy 13(10):841\u2013850. https:\/\/doi.org\/10.2217\/imt-2020-0296","journal-title":"Immunotherapy"},{"issue":"2","key":"5376_CR23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40744-020-00204-9","volume":"7","author":"K Kr\u00fcger","year":"2020","unstructured":"Kr\u00fcger K, Burmester GR, Wassenberg S, Thomas MH (2020) Golimumab as the first-, second-, or at least third-line biologic agent in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis: post hoc analysis of a noninterventional study in Germany. Rheumatol Ther 7(2):371\u2013382. https:\/\/doi.org\/10.1007\/s40744-020-00204-9","journal-title":"Rheumatol Ther"},{"issue":"1","key":"5376_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.semarthrit.2019.07.003","volume":"50","author":"B Michelsen","year":"2020","unstructured":"Michelsen B, Sexton J, Wier\u00f8d A, Bakland G, R\u00f8devand E, Kr\u00f8ll F, Kvien TK (2020) Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study. Semin Arthritis Rheum 50(1):12\u201316. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.07.003","journal-title":"Semin Arthritis Rheum"},{"key":"5376_CR25","doi-asserted-by":"publisher","unstructured":"D'Angelo S, Tirri E, Giardino AM et al (2022) Effectiveness of Golimumab as Second Anti-TNF\u03b1 Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study. J Clin Med 11(14):4178. https:\/\/doi.org\/10.3390\/jcm11144178","DOI":"10.3390\/jcm11144178"},{"issue":"5","key":"5376_CR26","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr.21649","volume":"64","author":"J Anderson","year":"2012","unstructured":"Anderson J, Caplan L, Yazdany J et al (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64(5):640\u2013647. https:\/\/doi.org\/10.1002\/acr.21649","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"5376_CR27","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.semarthrit.2017.10.021","volume":"47","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Coates LC (2018) Considerations for the definition of remission criteria in psoriatic arthritis. Semin Arthritis Rheum 47(6):786\u2013796. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.10.021","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"5376_CR28","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286\u20132291","journal-title":"J Rheumatol"},{"issue":"5 Suppl 39","key":"5376_CR29","first-page":"S93","volume":"23","author":"J Fransen","year":"2005","unstructured":"Fransen J, van Riel PL (2005) The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 23(5 Suppl 39):S93\u2013S99","journal-title":"Clin Exp Rheumatol"},{"key":"5376_CR30","doi-asserted-by":"publisher","unstructured":"Machado P, Landew\u00e9 R, Lie E et al (2011) Assessment of SpondyloArthritis international Society. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70(1):47\u201353. https:\/\/doi.org\/10.1136\/ard.2010.138594","DOI":"10.1136\/ard.2010.138594"},{"key":"5376_CR31","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/ard.2003.016386","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M, Listing J, Brandt J et al (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor \u03b1 blockers in ankylosing spondylitis. Ann Rheum Dis 63:665\u2013670. https:\/\/doi.org\/10.1136\/ard.2003.016386","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5376_CR32","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/annrheumdis-2013-203967","volume":"74","author":"U Kiltz","year":"2015","unstructured":"Kiltz U, van der Heiijde D, Boonen A et al (2015) Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 74(5):830\u2013835. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203967","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5376_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5):353\u2013365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"5376_CR34","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrrheum.2015.8","volume":"11","author":"JS Smolen","year":"2015","unstructured":"Smolen JS, Aletaha D (2015) Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 11(5):276\u2013289. https:\/\/doi.org\/10.1038\/nrrheum.2015.8","journal-title":"Nat Rev Rheumatol"},{"key":"5376_CR35","doi-asserted-by":"publisher","unstructured":"Rahman P, Zummer M, Bessette L, et al (2017) Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry. BMJ Open 7(8):e016619. https:\/\/doi.org\/10.1136\/bmjopen-2017-016619","DOI":"10.1136\/bmjopen-2017-016619"},{"issue":"12","key":"5376_CR36","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2217\/cer-2020-0092","volume":"9","author":"K Krueger","year":"2020","unstructured":"Krueger K, Remstedt S, Thiele A, Hohenberger S (2020) Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany. J Comp Eff Res 9(12):891\u2013902. https:\/\/doi.org\/10.2217\/cer-2020-0092","journal-title":"J Comp Eff Res"},{"issue":"1","key":"5376_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00296-018-4180-4","volume":"39","author":"K Kr\u00fcger","year":"2019","unstructured":"Kr\u00fcger K, Burmester GR, Wassenberg S, Bohl-B\u00fchler M, Thomas MH (2019) Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany. Rheumatol Int 39(1):131\u2013140. https:\/\/doi.org\/10.1007\/s00296-018-4180-4","journal-title":"Rheumatol Int"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05376-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-023-05376-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05376-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T10:04:36Z","timestamp":1692266676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-023-05376-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["5376"],"URL":"https:\/\/doi.org\/10.1007\/s00296-023-05376-5","relation":{},"ISSN":["1437-160X"],"issn-type":[{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"assertion":[{"value":"10 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"<i>Dr Prodromos Sidiropoulos<\/i> has received support for the present manuscript from MSD, in addition to research grants from Pfizer, Genesis, UCB, GSK, MSD, Abbvie, Novartis, Roche, Eli Lilly and Amgen. He has also received consultation payments from Pfizer, Abbvie and Eli Lilly, and honoraria from Pfizer, UCB, Abbvie, Novartis and Eli Lilly. He has received support for attending a Data Safety Monitoring Board or Advisory Board from Pfizer, Abbvie, Novartis and Eli Lilly. <i>Dr Dimitrios Vassilopoulos<\/i> has received support for the present manuscript from MSD<i>. Dr Periklis Vounotrypidis<\/i> has received support for the present manuscript from MSD, in addition to research grants from Abbvie, Genesis pharma and Novartis. <i>Dr Andreas Bounas<\/i> has received support for the present manuscript from MSD, in addition to grants or contracts from Abbvie, Amgen, Genesis, MSD, Novartis and Pfizer. He has also received honoraria from Abbvie, Aeonorasis, Amgen, Bausch Health, Faran, Genesis, GSK, Janssen, MSD, Novartis, Pfizer and UCB, as well as for participation on a Data Safety Monitoring Board or Advisory Board from Abbvie, Aeonorasis, Amgen, Bausch Health, Faran, Genesis, GSK, Janssen, MSD, Novartis, Pfizer and UCB. <i>Dr Anna Kandyli<\/i> has received consultation payments from Abbvie, Mylan and Genesis, as well as honoraria from Abbvie and Novartis. She has received support for attending meetings and\/or travel from UCB, and for participating on a Data Safety Monitoring Board or Advisory Board from Genesis and Amgen. <i>Dr Gkikas Katsifis<\/i> has received honoraria from Abbvie, Aenorasis, Amgen, Janssen, Jenessis, Lilly, MSD, Novartis, Sobi, Roche, Pfizer and UCB. Also, the author has received support for attending meetings from AbbVie, Sandoz, Roche, UCB, and Lilly, and for his participation on a Data Safety Monitoring Board or Advisory Board from ELPEN. <i>Dr Grigorios Sakellariou<\/i> has received support for the present manuscript from MSD, as well as research grants for education activities from Pfizer, Genesis, UCB, GSK, and MSD, and support for attending meetings and\/or travel from Abbvie and MSD. <i>Dr Maria Tektonidou<\/i> has received support for the present manuscript from MSD, as well as research grants from Genesis, UCB, GSK, MSD, and Amgen, and consultation payments from Genesis, GSK, Novartis and EI Lilly. <i>Zhiping Huang<\/i> is an employee of Merck & Co., Inc., Rahway, NJ, USA, and <i>Evangelia Petrikkou<\/i> is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who owns stock and\/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA. <i>Drs Panagiotis Athanassiou, Dimitrios Psaltis, Athanasios Georgiadis, Athina Theodoridou, Souzana Gazi, and Dimitrios Bounas have declared no conflicts of interest.<\/i>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the EU Directive 2001\/20\/EC section for non-interventional studies and the applicable laws and regulations of Greece. All included patients provided written informed consent before study entry. The present study was performed in accordance with the Helsinki declaration of 1964, and its later amendments. The study was approved by the competent Institutional Review Boards (IRBs) of all participating hospital sites. Participation of private practice investigators was approved by the IRB of a participating hospital located in the same geographic region as the Private Practice. Specifically, the IRBs that reviewed and approved the study, and corresponding ethical review reference numbers include IRB of \u201cLaiko\u201d General Hospital (reference number: 6046\/24-Apr-2018), IRB of \u201cKAT\u201d Regional General Hospital (reference number: 188\/14-Jun-2018), IRB of Private Practice under \u201cLaiko\u201d General Hospital (reference number: 59\/15-Feb-2018), IRB of University General Hospital of Heraklion, Crete (reference number: 17991\/22-Nov-2018), IRB of \u201cOlympion\u201dRehabilitation Center of Patras (reference number: 14-Mar-2018), IRB of Private Practice under University General Hospital of Ioannina (reference number: 5th\/08-Apr-2018), IRB of Private Practice under European Interbalkan Medical Center (reference number 17-Jan-2018), IRB of Private Practice under European Interbalkan Medical Center (reference number 22-Jan-2019), IRB of \u201cAttikon\u201d University General Hospital (reference number 5th\/29-May-2018), IRB of \u201cAg. Pavlos\u201d of Thessaloniki (reference number: 123\/08-Mar-2018), IRB of \u201cIppokrateio\u201dGeneral Hospital of Athens (reference number: 4552\/19-Mar-2018), IRB of Naval Hospital of Athens (reference number: 3\/18\/02-Apr-2018).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All persons gave their informed consent prior to their inclusion in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants provided consent for publication of the material collected in the context of this study in a non-identifiable manner.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}